色素-话题@MedSci

#色素#

654篇内容 | 6183人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1680757, encodeId=f6ed1680e57d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：伊匹单抗+纳武单抗治疗脑转移的黑色素瘤的3期试验的长期随访结果, objectType=article, longId=216644, objectId=8f082166443f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f082166443f, replyNumber=0, likeNumber=84, createdTime=2021-12-18, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f082166443f, moduleTitle=Clin Cancer Res：伊匹单抗+纳武单抗治疗脑转移的黑色素瘤的3期试验的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f082166443f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680748, encodeId=5ca11680e48ee, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力, objectType=article, longId=215634, objectId=2166215634d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2166215634d4, replyNumber=0, likeNumber=125, createdTime=2021-11-15, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2166215634d4, moduleTitle=INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2166215634d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680746, encodeId=ee421680e4615, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关, objectType=article, longId=215275, objectId=07ce2152e534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ce2152e534, replyNumber=0, likeNumber=66, createdTime=2022-05-10, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ce2152e534, moduleTitle=Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ce2152e534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680750, encodeId=fd941680e5093, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, objectType=article, longId=215840, objectId=dfc62158401b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc62158401b, replyNumber=0, likeNumber=73, createdTime=2022-03-16, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc62158401b, moduleTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc62158401b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680733, encodeId=22051680e3396, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=212747, objectId=5467212e47b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5467212e47b0, replyNumber=0, likeNumber=80, createdTime=2021-08-25, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5467212e47b0, moduleTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5467212e47b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680744, encodeId=05351680e44ff, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存, objectType=article, longId=214994, objectId=c253214994bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c253214994bf, replyNumber=0, likeNumber=97, createdTime=2022-01-15, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c253214994bf, moduleTitle=JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c253214994bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680725, encodeId=23fd1680e25c7, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性, objectType=article, longId=211237, objectId=ce0a21123ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce0a21123ee7, replyNumber=0, likeNumber=67, createdTime=2021-11-14, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce0a21123ee7, moduleTitle=JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce0a21123ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680759, encodeId=0fa31680e5984, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Dermatol Surg：皮秒vs.Nd: YAG激光治疗亚洲人表皮和真皮色素病变的效果, objectType=article, longId=217374, objectId=c29221e37443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c29221e37443, replyNumber=0, likeNumber=99, createdTime=2021-11-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c29221e37443, moduleTitle=Dermatol Surg：皮秒vs.Nd: YAG激光治疗亚洲人表皮和真皮色素病变的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c29221e37443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=60, createdTime=2021-09-14, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680721, encodeId=cea61680e216f, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Food Funct：富含甜菜红色素的仙人掌科（火龙果和仙人掌果）对于内皮和血管功能的影响：动物和人体研究的系统综述, objectType=article, longId=208371, objectId=93e42083e160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e42083e160, replyNumber=0, likeNumber=94, createdTime=2021-04-12, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e42083e160, moduleTitle=Food Funct：富含甜菜红色素的仙人掌科（火龙果和仙人掌果）对于内皮和血管功能的影响：动物和人体研究的系统综述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e42083e160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680743, encodeId=54791680e4334, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=74, createdTime=2022-04-04, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680728, encodeId=343a1680e28d0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Neuropsychopharmacology：神经黑色素敏感磁共振成像有助于监测多巴胺相关的精神运动减缓疾病, objectType=article, longId=212040, objectId=546a212040c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=546a212040c0, replyNumber=0, likeNumber=86, createdTime=2022-02-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=546a212040c0, moduleTitle=Neuropsychopharmacology：神经黑色素敏感磁共振成像有助于监测多巴胺相关的精神运动减缓疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=546a212040c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680755, encodeId=e4041680e558e, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Immunother Cancer：纳武单抗辅助治疗III/IV期黑色素瘤的安全性分析, objectType=article, longId=216630, objectId=3879216630e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3879216630e7, replyNumber=0, likeNumber=94, createdTime=2022-06-23, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3879216630e7, moduleTitle=J Immunother Cancer：纳武单抗辅助治疗III/IV期黑色素瘤的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3879216630e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680741, encodeId=55b11680e4115, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=66, createdTime=2022-02-19, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680709, encodeId=aae61680e0969, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Cell Death Differ：单细胞RNA测序揭示原发性葡萄膜黑色素瘤的肿瘤内异质性, objectType=article, longId=206126, objectId=a02b20612652, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02b20612652, replyNumber=0, likeNumber=67, createdTime=2021-02-27, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02b20612652, moduleTitle=Cell Death Differ：单细胞RNA测序揭示原发性葡萄膜黑色素瘤的肿瘤内异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a02b20612652)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680710, encodeId=ff391680e1015, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后, objectType=article, longId=206293, objectId=d65b206293e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d65b206293e7, replyNumber=0, likeNumber=96, createdTime=2021-09-01, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65b206293e7, moduleTitle=J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65b206293e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680715, encodeId=df581680e15d0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物, objectType=article, longId=207182, objectId=7bde20e182c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bde20e182c5, replyNumber=0, likeNumber=37, createdTime=2021-07-28, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bde20e182c5, moduleTitle=Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bde20e182c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680762, encodeId=a5201680e6279, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：新型免疫疗法出炉！“癌中之王”黑色素瘤或许有法可治了！, objectType=article, longId=217891, objectId=b6f821e89161, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6f821e89161, replyNumber=0, likeNumber=72, createdTime=2022-08-04, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6f821e89161, moduleTitle=Clin Cancer Res：新型免疫疗法出炉！“癌中之王”黑色素瘤或许有法可治了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6f821e89161)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680717, encodeId=e9c41680e1709, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, objectType=article, longId=207376, objectId=04bd20e376d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04bd20e376d9, replyNumber=0, likeNumber=78, createdTime=2021-03-22, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04bd20e376d9, moduleTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04bd20e376d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680745, encodeId=910f1680e45e3, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, objectType=article, longId=215238, objectId=cb2d215238b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d215238b4, replyNumber=0, likeNumber=57, createdTime=2022-04-03, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d215238b4, moduleTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d215238b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

色素

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：伊匹单抗+纳武单抗治疗脑转移的黑色素瘤的3期试验的长期随访结果

2021-12-18

sunylz (审核中...)

前往app查看评论内容

#色素#

INT J ONCOL：CSPG4单抗抑制黑色素瘤的侵袭力

2021-11-15

sunylz (审核中...)

前往app查看评论内容

#色素#

Mov Disord：神经黑色素变化，和帕金森病的恶化高度相关

2022-05-10

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后

2022-03-16

sunylz (审核中...)

前往app查看评论内容

#色素#

J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性

2021-08-25

sunylz (审核中...)

前往app查看评论内容

#色素#

JNCCN：伴有前哨淋巴结（SN）阳性以及SN包膜结外延伸（ENE）的黑色素瘤患者的生存

2022-01-15

sunylz (审核中...)

前往app查看评论内容

#色素#

JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性

2021-11-14

sunylz (审核中...)

前往app查看评论内容

#色素#

Dermatol Surg：皮秒vs.Nd: YAG激光治疗亚洲人表皮和真皮色素病变的效果

2021-11-07

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-09-14

sunylz (审核中...)

前往app查看评论内容

#色素#

Food Funct：富含甜菜红色素的仙人掌科（火龙果和仙人掌果）对于内皮和血管功能的影响：动物和人体研究的系统综述

2021-04-12

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2022-04-04

sunylz (审核中...)

前往app查看评论内容

#色素#

Neuropsychopharmacology：神经黑色素敏感磁共振成像有助于监测多巴胺相关的精神运动减缓疾病

2022-02-07

sunylz (审核中...)

前往app查看评论内容

#色素#

J Immunother Cancer：纳武单抗辅助治疗III/IV期黑色素瘤的安全性分析

2022-06-23

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2022-02-19

sunylz (审核中...)

前往app查看评论内容

#色素#

Cell Death Differ：单细胞RNA测序揭示原发性葡萄膜黑色素瘤的肿瘤内异质性

2021-02-27

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后

2021-09-01

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物

2021-07-28

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：新型免疫疗法出炉！“癌中之王”黑色素瘤或许有法可治了！

2022-08-04

sunylz (审核中...)

前往app查看评论内容

#色素#

转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”

2021-03-22

sunylz (审核中...)

前往app查看评论内容

#色素#

Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答

2022-04-03

科室
- - 订阅+
  - 更多科室
工具
服务